Drugs / AP30663
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04571385 | Sep 2019 → Dec 2022 | atrial fibrillation | Acesion Pharma | Completed | Met primary |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2023-12-13 | Acesion Pharma | Results Acesion Pharma announces Nature Medicine publication of clinical results in Atrial Fibrillation acesionpharma.com ↗
The primary endpoint occurred in 42% (5 of 12), 55% (12 of 22) and 0% (0 of 25) of patients treated with 3 mg/kg AP30663, 5 mg kg/1 AP30663, or placebo, respectively. |
| 2023-03-14 | Acesion Pharma | Results Positive phase 2 data from Atrial Fibrillation clinical trial – primary endpoint met acesionpharma.com ↗ |
| 2018-11-05 | Acesion Pharma | Results Acesion Pharma Announces Positive Results for Novel Drug Targeting Atrial Fibrillation acesionpharma.com ↗
Acesion Pharma (“Acesion” or the Company), a Danish biotech company developing novel treatments for atrial fibrillation (AF), the most common cardiac arrhythmia, announces positive results from the Phase 1 clinical trial of its lead compound AP30663. |
| 2018-02-08 | Acesion Pharma | Regulatory Acesion Pharma Receives Approval for Phase I Study in Atrial Fibrillation acesionpharma.com ↗
Acesion Pharma (“Acesion” or the Company), a Danish biotech company developing novel treatments for atrial fibrillation (AF), the most common cardiac arrhythmia, announces today it has received approval to commence its first clinical study for its lead compound AP30663. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-12-13 | Acesion Pharma | Acesion Pharma announces Nature Medicine publication of clinical results in Atrial Fibrillation acesionpharma.com ↗ |
| 2023-03-14 | Acesion Pharma | Positive phase 2 data from Atrial Fibrillation clinical trial – primary endpoint met acesionpharma.com ↗ |
| 2018-11-05 | Acesion Pharma | Acesion Pharma Announces Positive Results for Novel Drug Targeting Atrial Fibrillation acesionpharma.com ↗ |
| 2018-02-08 | Acesion Pharma | Acesion Pharma Receives Approval for Phase I Study in Atrial Fibrillation acesionpharma.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AP30663 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04571385 ↗ |
| Action | Inhibit | “AP30663, an inhibitor of the KCa2 channel” PMID 38092897 ↗ Dec 2023 |
| Route | Intravenous | “Administer by intravenous infusion.” NCT04571385 ↗ |